Details about the neuroanatomical projections from CA1 to PAA
To view more data and metadata associated with each report, click on its ID.
| Report ID | Sending structure |
Receiving structure | Projection strength | Technique | General description projection | Collator | Associated reference |
|---|
| 88637 |
Field CA1 | Piriform-amygdaloid area |
light | biotinylated dextran amine (BDA) | Many of other amygdaloid nuclei showed extremely light labeling (Fig. 4A–D). Collator note: Fig 4A-D, Swanson Atlas Levels 26-32. | Kishi T., Tsumori T., Yokota S. & Yasui Y.
, 2006 |
|---|
| 88690 |
Field CA1 | Piriform-amygdaloid area |
light/moderate | biotinylated dextran amine (BDA) | At caudalmost levels, CA1 fibers labeled with BDA relatively densely terminated in the dorsomedial portion of the PLCo and in the amygdalopiriform transition area (APir). Collator note: unclear whether this terminal field is only in COApl, or it extends into COApm. See Fig. 7D, Swanson Atlas Levels 31-32. | Kishi T., Tsumori T., Yokota S. & Yasui Y.
, 2006 |
|---|
|
General description technique/protocol: In case R53, BDA was injected into a temporal portion of field CA1 that abuts on the rostral Sv (Fig. 1A). Collator note: injection completely included in the CA1, rostro-ventral. The injection site is annotated here onto Swanson Atlas Level 37 (-5.3 mm f |
Further details associated to record number 88637:
| Position of injection: rostro-ventral |
| Topological position of injection: is contained |
| Extension of injection outside: none |
| The injection was performed in: left hemisphere |
| | Position of terminal field: everywhere |
| Topological position of terminal field: is contained |
| Extension of terminal field outside: none |
| The terminal field was found: ipsilateral |
| |
